The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer
Abstract
Purpose: A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of antiangiogenic therapies. Pericytes have been revealed as functionally important for tumor neovasculature, using kinase inhibitors targeting their platelet-derived growth factor receptors (PDGFRs). Additionally, vascular endothelial growth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against early- but not late-stage disease. Materials and Methods: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition. Results: Imatinib, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition. A regimen involving all three was even better. MTD using cyclophosphamide caused transitory regression, but then rapid regrowth, in contrast to metronomic cyclophosphamide plus imatinib, which produced stable disease. The MTD regimen elicited apoptosis of tumor cells but not endothelial cells, whereas the other regimens increased endothelial cell apoptosis concordant with efficacy. A “chemo-switch” protocol, involving sequential MTD and then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave complete responses and unprecedented survival advantage in this model. Conclusion: This study demonstrates a potentially tractable clinical strategy in a stringent preclinical model, wherein standard-of-care chemotherapy is followed by a novel maintenance regimen: PDFGR is targeted to disrupt pericyte support, while metronomic chemotherapy and/or VEGFR inhibitors target consequently sensitized endothelial cells, collectively destabilizing pre-existing tumor vasculature and inhibiting ongoing angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice
Lindahl, P., Johansson, B. R., Levéen, P., & Betsholtz, C. (1997) · Science · doi:10.1126/science.277.5323.242 · Cited by 2,226
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Self-citationBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Self-citationHanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Anti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,057
Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.
Soriano, P. (1994) · Genes & Development · doi:10.1101/gad.8.16.1888 · Cited by 989
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Self-citationLess is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Self-citationHirschi, K. K., Rohovsky, S. A., & D'Amore, P. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.3.805 · Cited by 796
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall
Lindblom, P., Gerhardt, H., Liebner, S., Abramsson, A., Enge, M., Hellström, M., Bäckström, G., Fredriksson, S., Landegren, U., Nyström, H. C., et al. (2003) · Genes & Development · doi:10.1101/gad.266803 · Cited by 657
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Abramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562
PDGF receptors as cancer drug targets
Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., & Östman, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00089-8 · Cited by 465
Self-citationInhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
Self-citationRhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Self-citationAntiangiogenic therapy of transgenic mice impairs de novo tumor growth.
Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., & Hanahan, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.2002 · Cited by 344
Self-citationMan, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Self-citationSundberg, C., Kowanetz, M., Brown, L. F., Detmar, M., & Dvorak, H. F. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780433 · Cited by 253
Metronomic scheduling: the future of chemotherapy?
Gasparini, G. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00587-3 · Cited by 251
Furuhashi, M., Sjöblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., Bergsten-Folestad, E., Eriksson, U., Heuchel, R., Betsholtz, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1489 · Cited by 203
Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., et al. (2001) · PubMed · Cited by 181
Jayson, G. C., Parker, G. J. M., Mullamitha, S., Valle, J. W., Saunders, M., Broughton, L., Lawrance, J., Carrington, B., Roberts, C., Issa, B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.032 · Cited by 165
Cao, Y. (2004) · The biomedical & life sciences collection. · doi:10.1016/j.semcancer.2003.09.018 · Cited by 148
Emmenegger, U., Man, S., Shaked, Y., Francia, G., Wong, J. W., Hicklin, D. J., & Kerbel, R. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0580 · Cited by 133
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 130
Severe periorbital edema secondary to STI571 (Gleevec)
Esmaeli, B., Prieto, V. G., Butler, C. E., Kim, S. K., Ahmadi, M., Kantarjian, H. M., & Talpaz, M. (2002) · Cancer · doi:10.1002/cncr.10729 · Cited by 117
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
Broxterman, H. J., Lankelma, J., & Hoekman, K. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00026-8 · Cited by 91
Role of Platelet-Derived Growth Factors in Angiogenesis and Alveogenesis
Lindahl, P., Boström, H., Karlsson, L., Hellström, M., Kalén, M., & Betsholtz, C. (1999) · Current topics in pathology · doi:10.1007/978-3-642-58456-5_4 · Cited by 85
Increasing tumor uptake of anticancer drugs with imatinib
Pietras, K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.036 · Cited by 61
Self-citationSano, H., Ueda, Y., Takakura, N., Takemura, G., Doi, T., Kataoka, H., Murayama, T., Xu, Y. Y., Sudo, T., Nishikawa, S., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64165-x · Cited by 52
Cerebral oedema as a possible complication of treatment with imatinib
Ebnöther, M., Stentoft, J., Ford, J., Buhl, L., & Gratwohl, A. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08616-6 · Cited by 49
Patel, N., Sun, L., Moshinsky, D. J., Chen, H., Leahy, K. M., Le, P., Moss, K. G., Wang, X., Rice, A. G., Tam, D., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052167 · Cited by 41
Bergers, G., & Hanahan, D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.293 · Cited by 29
Self-citationAntiangiogenic therapy targeting factors that enhance endothelial cell survival
LIU, W., Reinmuth, N., Stoeltzing, O., Parikh, A. A., FAN, F., Ahmad, S., JUNG, Y., & Ellis, L. M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70132-2 · Cited by 22
Role of Methotrexate in the Treatment of Acute Lymphoblastic Leukemia
Camitta, B. M., & Kamen, B. A. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-307-1_26 · Cited by 6
(2000) · doi:10.1002/1097-0177(200007)218:3<472::aid-dvdy1008>3.0.co;2-#
Cited by
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Self-citationThe role of pericytes in blood-vessel formation and maintenance
Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,141
Self-citation
Metadata
- Authors
- Pietras, K., & Hanahan, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-10
- Volume
- 23
- Issue
- 5
- Pages
- 939-952
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2034548257
- Cited by
- 479
- References
- 51
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.